Global zika virus industry 2017 market research report

Global Zika Virus Industry 2017 Market Research Report Email: sale@qyresearch.com Tel:0086-20-86655165 http://www.qyresearch.com

Global Zika Virus Industry 2017 Market Research Report

1

Author: Meng Xiaoping

Company: QYR Pharma & Healthcare Research Center Publish Date: 2017/06/02

Zika virus disease (Zika) is a disease caused by the Zika virus, which is spread to people primarily

through the bite of an infected Aedes species mosquito. The most common symptoms of Zika are fever,

rash, joint pain, and conjunctivitis. The illness is usually mild with symptoms lasting for several days to a week after being bitten by an infected mosquito. Based on research to date, there is scientific consensus that Zika virus is a cause of microcephaly and GBS.

Zika virus is primarily transmitted to people through the bite of an infected mosquito from the Aedes

genus, mainly Aedes aegypti in tropical regions. Sexual transmission of Zika virus is also possible. Other modes of transmission such as blood transfusion are being investigated.

Zika virus is a mosquito-borne flavivirus that was first identified in Uganda in 1947 in monkeys through a network that monitored yellow fever. It was later identified in humans in 1952 in Uganda and the

United Republic of Tanzania. Outbreaks of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific. From the 1960s to 1980s, human infections were found across Africa and Asia,

typically accompanied by mild illness. The first large outbreak of disease caused by Zika infection was

reported from the Island of Yap (Federated States of Micronesia) in 2007. In July 2015 Brazil reported an association between Zika virus infection and Guillain-BarrĂŠ syndrome. In October 2015 Brazil reported an association between Zika virus infection and microcephaly.

Current Zika Transmission Situation by Countries: Argentina, Aruba, Barbados, Belize, Bolivia, Bonaire, Brazil, Colombia, Commonwealth of Puerto Rico, US territory Costa Rica, Cuba, Curacao, Dominica,

Global Zika Virus Industry 2017 Market Research Report

2

Dominican Republic, Ecuador, El Salvador, French Guiana, Grenada, Guadeloupe, Guatemala, Guyana,

Haiti, Honduras, Jamaica, Martinique, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Barthelme, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Sint Maarten, Suriname, Trinidad and Tobago, U.S.

Virgin Islands, Venezuela, American Samoa, Fiji, Kosrae, Federated States of Micronesia, Marshall Islands, New Caledonia, Papua New Guinea, Samoa, Tonga, Indonesia, Philippines, Thailand, Cape Verde

Fears are mounting as the mosquito-borne Zika virus spreads to 23 countries in the Americas, with the

World Health Organization forecasting a potential 3 million to 4 million cases of the virus in the region.

Now there have severy Companies Research Zika Virus: Bharat Biotech, Inovio Pharmaceuticals,

GeneOne Life Sciences, Intrexon, Cerus, Sanofi, NewLink Genetics, Immunovaccine, GlaxoSmithKline and etc.

Zika virus is mainly marketed by two companies: ATCC (headquartered in the US) and LGC Standards (headquartered in the UK) (ATCC-LGC Partnership).

But, there also have a company, ZeptoMetrix, producting NATtrol Zika Virus-External Run Control-Low (6 x 1 mL).

Bharat has patented the Zika vaccine. The company has sought the direct intervention of Prime Minister Narendra Modi to ensure that the vaccine's development and delivery is fast-tracked, cutting through the red tape of regulatory clearances. The company official said it can make one million doses of the vaccine in four months.

Inovio Pharmaceuticals and GeneOne Life Science announced that testing of its synthetic vaccine for the Zika virus induced robust antibody and T cell responses in non-human primates (monkeys),

Global Zika Virus Industry 2017 Market Research Report

3

demonstrating the product’s potential to prevent infection from this harmful pathogen.

Simultaneously, the vaccine could move to human testing by the end of the year.

There more and more companies and institutions internationally were developing vaccines against Zika, but none had yet reached clinical trials. And it may take more than two years to develop a vaccine, but

about ten years may be needed before an effective Zika vaccine is approved by regulators for public use.

This article was first released by QYResearch analyst, if reproduced, please indicate the source.

Media Contact: press@qyresearch.com

Analyst : mengxiaoping@qyresearch.com

Global Zika Virus Industry 2017 Market Research Report

4